"Designing Growth Strategies is in our DNA"

Psoriatic Arthritis Treatment Market Size, Share & COVID-19 Impact Analysis, By Drugs Class (Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Others), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecast, 2020-2027

Region : Global | Format: PDF | Report ID: FBI101066

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The global psoriatic arthritis treatment market size was valued at USD 6.35 billion in 2019 and is projected to reach USD 13.12 billion by 2027, exhibiting a CAGR of 9.5% during the forecast period.

COVID-19 Cover

This report covers COVID-19 impact analysis on Psoriatic Arthritis Treatment Market

Request Sample

Increasing prevalence of psoriatic arthritis, an autoimmune disorder caused by an attack of the body’s immune system on joints and skin is poised to drive the demand for psoriatic arthritis drugs for treatment. The disease is more prevalent among the patients already suffering from plaque psoriasis. According to a study published by Celgene Corporation, about 30% of the patients with psoriasis develop inflammatory condition involving joints, known as psoriatic arthritis.


Stressful lifestyles resulting in the overstimulation of immune system; rapidly increasing geriatric population, growing prevalence of psoriasis, rising income that increases affordability for high cost biologic products, and the rise in the number of new product approvals are some of the major factors contributing to the psoriatic arthritis treatment market growth. For instance, on March 2019, AbbVie announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) approved its Skyrizi (risankizumab) for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis, and psoriatic arthritis disease in adults who haven’t responded to conventional therapies.


COVID-19 Pandemic to Negatively Impact the Market


The COVID-19 pandemic has altered an approach of treatment to the patients requiring close contact with healthcare facilities. Psoriatic Arthritis patients are increasingly adopting telehealth facilities and online pharmacy solutions for getting prescriptions and medications delivered at home. Moreover, the psoriatic patients have multiple co-morbidities such as heart diseases, diabetes, stress, anxiety, and other psychological disorders. Undergoing studies focused on stopping immunosuppressant drugs use among the PsA patients during the COVID-19 pandemic. However, the American Journal of Clinical dermatology has concluded that, there is no increased risk of getting COVID-19 infections to the patients taking immunosuppressant medications. Although, these patients are known to have increased duration of infection caused by adenovirus, influenza, and norovirus; this has not been observed with the coronavirus family such as SARS-CoV-2 or MERS-CoV.


The COVID-19 pandemic had minimal impact on the PsA treatment market. The telehealth services being offered by the healthcare facilities are proving useful to support the PsA patients despite the unavailability of the dermatologists amid lockdown situation.


LATEST TRENDS


Request a Free sample to learn more about this report.


Growing Biologic Drugs Penetration in Treatment of Psoriatic Arthritis


Psoriasis is a chronic inflammatory skin condition which extends to joints in the case of PsA’s. The condition has been traditionally treated with phototherapy and the non-biologic disease modifying agents such as methotrexate, and cyclosporine among others. Increasing research activities on large molecules has resulted in an upsurge in the development of biologics and biosimilar drugs with enhanced effectiveness and positive therapeutic outcomes. Increasing expenditure on the development of advanced therapies, new product approvals, and the rise in the adoption of high cost biological drugs across the globe has resulted in increased penetration of biologics in the management of PsA in recent years.


DRIVING FACTORS


Rise in Prevalence of Psoriatic Arthritis to Fuel Market Growth


A steady rise in the prevalence of PsA across the globe has been observed in recent years, attributable to factors such as aging population, stressful lifestyles, genetic changes, and growing life expectancy. According to the study published by NCBI in the year 2014, the prevalence of the disease varies significantly among different regions of the world. For example, the incidence of PsA varies from 0.1/100000 in Japan to 23.1/100000 in Finland. The prevalence of PsA in Europe and America varies from 0.02%-0.42%. Moreover, the study suggests that the prevalence of the disease is more common in developed regions of the world as compared to Asia and other emerging regions. According to the National Psoriasis Foundation (NPF), in 2017, around 125 million people globally had psoriasis, out of which 10-20% population developed psoriasis arthritis. Thus, continuously rising patient population is projected to augment the growth of the market during the forecast period.


Presence of Strong Pipeline of Drugs to Spur Market Growth


A recent wave of biologic products prescribed for the treatment of PsA is likely to double the market revenue by the end of 2026. Biologics are the targeted drugs developed from generic engineering of proteins. These are being increasingly recommended by dermatologists owing to their effectiveness to reduce the symptoms of the disease despite their high cost. This leverages a great market potential for investment in the novel product developments and clinical trials. For instance, Mirikizumab, a biologic drug, has shown 82% improvement in the symptoms with Psoriasis. Additionally, growing strategic collaborations and mergers among various key players are likely to enhance the penetration of innovative products in the coming years.


RESTRAINING FACTORS


Adverse Effects, Stringent Regulations, and Patent Expiry of Drugs to Restrict Market Growth


Biologic medications showing effectiveness against the severe cases of psoriatic arthritis are increasingly being adopted these days. However, their adoption is limited by high cost of these products. Economically weak regions with low expenditure on healthcare and poor reimbursement scenario poses a threat to the penetration of these products in the developing markets with significant addressable population. Moreover, the market faces some of the major challenges such as high cost of biologic products making them unaffordable to the population in emerging regions, delay in diagnosis, gaps in clinical management, and lack of consensus on treatment outcomes.


SEGMENTATION


By Drug Class Analysis


To know how our report can help streamline your business, Speak to Analyst


Biological DMARDs Drugs to Account for Maximum Psoriatic Arthritis Treatment Market Shares due to High Cost of Treatment


Based on drug class, the market for psoriatic arthritis treatment segments include non-steroidal anti-inflammatory drugs (NSAIDs), non-biologic disease modifying anti-rheumatic drugs (DMARDs), biologic disease modifying anti-rheumatic drugs (DMARDs), and others. Among them, the DMARDs biologics segment dominated the market, with 63.8% share in the year 2019. This segment is likely to continue its dominance throughout the forecast period attributable to the growing adoption of biological therapies due to their efficacy towards the management of the disease.


By Route of Administration Analysis


Parenteral Route Segment to Exhibit Significant CAGR Owing to Growing Adoption of Biological Drugs.


Based on route of administration, the parenteral route accounted for largest revenue share for psoriatic arthritis treatment in the year 2019. Biological drugs are designed to be administered via systemic route. Parenteral or systemic administration of the drugs offers immediate concentration of the drugs in the blood while avoiding the first pass effect. These advantages offered by the systemic route, high cost of the injectable products, and growing adoption of advanced therapies for the management of the disease contributes to the dominance of the segment. The segment is expected to continue its leading position during the forecast period due to increasing number of product launches in the biologics category.


By Distribution Channel Analysis


Hospital Pharmacies Segment Likely to Hold Major Chunk of the Market


In terms of distribution channel, the market for psoriatic arthritis treatment is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment is projected to emerge dominant during the forecast period. Highest preference given to the hospitals for the management of critical conditions, increasing use of systemic therapies, and availability of skilled healthcare providers are factors contributing to the highest preference to these facilities.


However, the online pharmacies segment is likely to expand at the highest CAGR owing to increasing use of internet across globe, convenience of online shopping, and multiple discounts offered by online pharmacy sites.


REGIONAL INSIGHTS


North America Psoriatic Arthritis Treatment Market Size, 2019 (USD Billion)

To get more information on the regional analysis of this market, Request a Free sample


The market size for Psoriatic Arthritis Treatment in North America stood at USD 2.78 billion in 2019. The growing burden of psoriatic arthritis in the North American countries is likely to drive the demand for the novel and effective treatment options for its management. The region is likely to continue its dominance throughout the forecast period attributable to high adoption of biological therapies, high research and development expenditure by the players in the region on clinical trials on disease management, and speedy new drug approvals by USFDA. According to the press release by the leading player Amgen Inc., there are more than 600,000 Americans who have psoriatic arthritis. Followed by North America, Europe emerged as the second largest market for PsA treatment. Asia Pacific region is projected to expand at the highest growth rate during the forecast period due to improving healthcare infrastructure, growing healthcare expenditure, and penetration of novel biologics in the region. Latin America and the Middle East & Africa regions were found to be the emerging markets leveraging a great opportunity for the players willing to establish their footprints in these regions.


KEY INDUSTRY PLAYERS


Janssen Global Services, LLC Joined Race of Psoriatic Arthritis Giants with their Recently Approved TREMFYA (guselkumab)


Psoriatic arthritis treatment market is a fairly consolidated market with industry behemoths holding a major share. AbbVie held a leading position with its leading brand, Humira, which is still the most prescribed biologic for the management of the disease. There is an increasing competition to launch the biological therapies for the management of the disease. The recent approval of TREMFYA (guselkumab) by USFDA in July 2020 as the first selective Interleukin (IL)-23 inhibitor has intensified the competition for established players. Other prominent players in the market includes industry giants such as Novartis AG, Pfizer Inc., Amgen, Merck, and others.


LIST OF KEY COMPANIES PROFILED:



  • F. Hoffmann-La Roche Ltd (Basel, Switzerland)

  • Novartis AG (Basel, Switzerland)

  • Amgen (Califormia, United States)

  • Pfizer Inc. (New York, United States)

  • Johnson & Johnson Services, Inc. (New Jersey, United States)

  • Eli Lilly and Company (Indiana, United States)

  • AstraZeneca (Cambridge, United Kingdom)

  • Sanofi (Paris, France)

  • Bristol-Myers Squibb Company (New York, United States)

  • GlaxoSmithKline plc. (Brentford, United Kingdom)

  • Bayer AG (Leverkusen, Germany)

  • Other Players


KEY INDUSTRY DEVELOPMENTS:



  • March 2019- AbbVie Inc. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved SKYRIZI (risankizumab), an interleukin-23 (IL-23) inhibitor, for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies.

  • October 2018- Novartis AG announced that the European Commission (EC) has approved a label update for Cosentyx (secukinumab).

  • December 2017 Pfizer Inc. announced that USFDA has approved its product type called Infliximab, a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.


REPORT COVERAGE


An Infographic Representation of Psoriatic Arthritis Treatment Market

To get information on various segments, share your queries with us



The report provides a detailed analysis of the market research and focuses on key aspects such as leading companies, drug class, route of administration, and distribution channels. Besides this, the report offers insights into the market, current trends, and highlights the key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the advanced market for Psoriatic Arthritis Treatment over the recent years.


To gain extensive insights into the market, Request for Customization


Report Scope & Segmentation











































 ATTRIBUTE



  DETAILS



Study Period



  2016-2027



Base Year



  2019



Forecast Period



  2020-2027



Historical Period



  2016-2018



Unit



  Value (USD Billion)



Segmentation



By Drug Class



  • Non-steroidal Anti-inflammatory Drugs (NSAIDS)

  • Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)

  • Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)

  • Others



By Route of Administration



  • Oral

  • Parenteral

  • Topical



By Distribution Channel



  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies



By Geography



  • North America (the U.S., and Canada)

  • Europe (the U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)

  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)

  • Latin America (Brazil, Mexico, and the Rest of Latin America)

  • The Middle East & Africa (South Africa, GCC and the Rest of the Middle East & Africa)



 


Frequently Asked Questions

Fortune Business Insights says that the global psoriatic arthritis treatment market size was USD 6.35 billion in 2019 and is projected to reach USD 13.12 billion by 2027.

In 2019, the North America market value stood at USD 2.78 billion.

Growing at a CAGR of 9.5%, the market will exhibit steady growth in the forecast period (2020-2027).

The biologic DMARD drug segment is expected to be the leading segment in this market by drug class during the forecast period.

Increasing prevalence of PsA and presence of strong pipeline of drugs are major factors driving the growth of the market.

AbbVie Inc., Amgen, and Novartis AG are major players of the global market.

North America dominated the market share in 2019.

Launch of advanced drug therapies by market players are expected to drive the adoption in the global market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
Psoriatic Arthritis Treatment Market Size, Share and Global Industry Trend Forecast till 2026
  • Sep, 2020
  • 2019
  • 2016-2018
  • 160

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X